grant
Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection
Organization GEORGE WASHINGTON UNIVERSITYLocation WASHINGTON, UNITED STATESPosted 1 Sept 2022Deadline 29 Feb 2028
NIHUS FederalResearch GrantFY2026ATAC sequencingATAC-seqATACseqActive Follow-upAffectAfter CareAfter-TreatmentAftercareAlpha VirusAmericanAnalgesia TestsArthritisAssay for Transposase-Accessible Chromatin using sequencingAtrophic ArthritisAutoimmune MechanismAutoimmune ProcessB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellBiopsyBiopsy SampleBiopsy SpecimenBlood leukocyteBody TissuesC2B8 Monoclonal AntibodyCHIKVCHIKV arthritisCHIKV infectionCaliforniaCell LineageChemotactic CytokinesChikungunya arthritisChikungunya virusChronicClinicalColombiaCulicidaeDegenerative ArthritisDegenerative polyarthritisDiseaseDisease OutbreaksDisorderDoseDrugsEvaluationEvidence based treatmentFolateFolic AcidGene ExpressionGoalsGroup A ArbovirusesGuidelinesHomologous Chemotactic CytokinesImmuneImmunesImmunoassayImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodIndividualInfectionInfiltrationInflammatoryIntercrinesJAK kinaseJanus kinaseLeukocytesLeukocytes Reticuloendothelial SystemMabTheraMacrophageMarrow leukocyteMeasuresMediatingMedicationMethotrexateMethotrexate MethylaminopterinMethotrexatumMetotrexatoMosquitoesMφNociception TestsOralOsteoarthritisOsteoarthrosisOutbreaksOutcomePainPain AssessmentPain MeasurementPain measurePainfulPathogenicityPathologicPatient Outcomes AssessmentsPatient Reported MeasuresPatient Reported OutcomesPatientsPersonsPharmaceutical PreparationsPlacebosProteinsPteroylglutamic AcidQOLQuality of lifeRandomizedRandomized, Controlled TrialsRecommendationReportingRheumatoid ArthritisRheumatologyRituxanRoleSIS cytokinesSeverity of illnessSham TreatmentSynoviaSynovial FluidSynovitisT-Cell ActivationT-CellsT-LymphocyteTherapeuticTherapeutic AgentsTissue SampleTissuesUnited StatesUniversitiesViral ArthritisVirus-induced arthritisVitamin MWhite Blood CellsWhite CellWorkactivate T cellsactive followuparmarthriticassay for transposase accessible chromatin followed by sequencingassay for transposase accessible chromatin seqassay for transposase accessible chromatin sequencingassay for transposase-accessible chromatin with sequencingchemoattractant cytokinechemokinechikungunyachikungunya infectionchikungunya viral arthritischikungunya virus arthritischikungunya virus infectionchikungunya virus-induced arthritiscollegecollegiatecytokinedegenerative joint diseasedetermine efficacydisabilitydisease severitydrug/agentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyevidence baseexamine efficacyfollow upfollow-upfollowed upfollowuphypertrophic arthritisimprovedinfected with CHIKVinfected with chikungunyainflamed synovial tissueinflamed synoviumkinase inhibitornovelopen labelopen label studypain assaypatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespost treatmentprimary end pointprimary endpointrandomisationrandomizationrandomized control trialrandomized placebo control trialrandomized placebo controlled trialrandomly assignedresponserheumatic arthritisrituximabscRNA sequencingscRNA-seqsecondary end pointsecondary endpointsham therapysingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsocial rolestandard carestandard treatmentsynovial inflammationtherapeutic targettherapeutically effectivethymus derived lymphocytetreatment guidelinesvitamin Bcwhite blood cellwhite blood corpuscle
Description preview
ABSTRACT
Chikungunya virus (CHIKV) is an alphavirus spread by mosquitos that causes persistent arthritis in
approximately 25% of people two years after initial infection. There is currently no standard evidence-based
treatment for CHIKV chronic arthritis. The French guidelines suggest the use of methotrexate in the treatment
of chronic CHIKV…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click